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Summary 
OptoGluNAM4.1, a negative allosteric modulator (NAM) of metabotropic glutamate receptor 
4 (mGlu4) contains a reactive group that covalently binds to the receptor and a blue light-
activated, fast relaxing azobenzene group that allows the reversible receptor activity 
photocontrol in vitro and in vivo. OptoGluNAM4.1 induces light-dependent behavior in 
zebrafish and reverses the mGlu4 agonist LSP4-2022 activity in a mice model of chronic pain, 
defining a photopharmacological tool to better elucidate the physiological roles of mGlu4 
receptor in the nervous system.  
Introduction 
Photopharmacology is based on the use of light sensitive ligands for the optical control of 
specific proteins in cells, tissues or live animals. This innovative and unconventional approach 
uses light for the precise control of drug activity, which in combination with spatio-temporal 
patterns of illumination can enable localized therapeutic effects and dosage adjustment to 
maximize efficacy and minimize side-effects (Gorostiza and Isacoff, 2008). The photochromic 
ligands can rapidly and reversibly switch on or off the activity of a protein with light in 
delimited and specific localizations and time intervals, and have the potential for precise drug 
therapeutics (Reiner et al., 2015). G-protein-coupled receptors (GPCRs) represent a large 
family of transmembrane receptors with fertile therapeutic targets for drug development 
(Conn et al., 2009). Metabotropic glutamate (mGlu) receptors are class C GPCRs that play 
important roles in a broad range of central nervous system (CNS) functions with promise for 
the treatment of various psychiatric and neurological disorders (Nicoletti et al., 2011). In 
particular, the mGlu4 subtype has recently attracted much attention due to its involvement in 
several diseases, including chronic pain (Huang et al., 2014).  
Owing to the difficulty in developing subtype selective orthosteric ligands, significant effort has 
been recently directed towards identifying drugs that act at mGlu receptor allosteric sites 
(Conn et al., 2009; Wenthur et al., 2014). Azobenzene-containing photoswitchable molecules 
have been used for optical control of mGlu receptors at their orthosteric (Levitz et al., 2013) 
and allosteric (Pittolo et al., 2014) sites.  
 
Results and Discussion 
In the present work, OptoGluNAM4.1 (compound 1, Figure 1a) emerged from a screening of 
photoisomerizable azobenzene molecules as an antagonist, decreasing both mGlu4 basal and 
orthosteric agonist mediated activities in a dose-dependent manner (Figure 1b, left top panel 
and Figure S1). A saturation of the inhibitory effect indicated either an allosteric behavior of 
the drug or to solubility issues. In order to test the allosteric properties of OptoGluNAM4.1 we 
performed a series of experiments with either the full receptor (Figure 1b, right top panel), the 
receptor containing a mutation that renders mGlu4 insensitive to glutamate (Figure 1b, left 
bottom panel) and a headless truncated version that lacks the extracellular domain where 
orthosteric agonists bind (Figure 1b, right bottom panel). These receptor constructs were 
activated by the known allosteric agonist VU0155041 (Rovira et al., 2015) and competed with 
increasing concentrations of OptoGluNAM4.1, which reduced mGlu4 activation. Overall, these 
results confirmed the interaction of the molecule in an allosteric site located in the 
transmembrane domain and having a typical profile of negative allosteric modulator (NAM), 
which is to our knowledge the second mGlu4 NAM described so far (Utley et al., 2011) in 
contrast with the high number of positive allosteric modulators (PAMs) discovered for this 
receptor (Rovira et al., 2015). OptoGluNAM4.1 showed no PAM activity over any mGlu subtype 
at high concentrations and, besides the mGlu4 NAM activity, only a partial NAM effect on 
mGlu7 was observed (Figure S1).   A computational study performed with a molecular model of 
the mGlu4 receptor (Figure 1c) suggeststhe OptoGluNAM4.1 interaction in the transmembrane 
domain, similar to that of PAMs of mGlu4 (Rovira et al., 2015) and NAMs of mGlu1 and mGlu5 
(Harpsøe et al., 2015).  The mutation of two amino acid positions (L756S and V826M) was 
aimed at topologically delimiting the boundaries of the putative allosteric binding site in the 
mGlu4 protein (Figure S1 and Movie S1). When OptoGluNAM4.1 was tested on L756S mGlu4 
cells, its inhibitory potency was increased over that of wt protein, while the V826M mutation 
was less sensitive to the ligand than wt mGlu4, indicating that the molecule occupies the whole 
allosteric pocket (Figure 1d) and further supporting the binding mode proposed. Consistently, 
these mutations did not alter the potency of the mGlu4 orthosteric agonist L-AP4 (Figure S1). 
The inclusion of an azobenzene group within the chemical structure of a drug confers potential 
photochromic activity to the molecule (Broichhagen et al., 2015). Two common properties of 
reported azobenzene ligands impose limitations for biological applications. First, the light 
source used to induce the trans to cis isomerization is usually in the UV-violet range, which is 
arguably not optimal for in vivo applications because of reduced tissue penetration and 
potential cell damage. The second limitation derives from the thermal stability of cis-
azobenzene in the dark, which may require a second wavelength illumination to return to the 
trans isomer for efficient switching. In the present work, we could circumvent these possible 
drawbacks since OptoGluNAM4.1 isomerizes with blue light and shows a quick back-
isomerization when dark conditions are recovered (Figure 2a). OptoGluNAM4.1 exhibits a wide 
visible absorption band and light sources from 420 nm to 460 nm were found to produce 
efficient trans to cis photoisomerization (Figure 2b and S2A). This change was reversed by 
applying red light (630 nm) or by spontaneous thermal relaxation when the blue illumination 
was discontinued. Absorption was maintained in several light switching cycles (Figure S2A). 
Interestingly, cis to trans relaxation in dark was very fast (Figure 2c and S2A) and it should 
enable the photocontrol of mGlu4 activity with a single illumination wavelength (Chi et al.). 
Single cell calcium imaging experiments demonstrated the ability of OptoGluNAM4.1 to 
optically control mGlu4. Indeed, the application of OptoGluNAM4.1 in the dark impeded the 
activation of the receptor by L-AP4 and 430 nm illumination restored L-AP4 induced 
intracellular calcium responses (Figure 2d, S2B and Movie S2). The OptoGluNAM4.1 activity 
was only abolished upon illumination conditions and it was rapidly reestablished in the dark as 
as expected from its fast relaxation dynamics. The quantification of the single cell experiments 
showed significant differences between illuminated and dark situations (Figure 2e), whereas 
no light effect was found for the antagonism of L-AP4 induced-activity by LY341495, a general 
non-photoswitchable orthosteric antagonist of mGlu receptors  (Figure 2f).  
The OptoGluNAM4.1 molecule contains a 2-chloroethyl substituent at nitrogen, similar to that 
present in drugs such as chlorambucil or bendamustine, which belong to the nitrogen mustard 
family of anticancer agents. It is well known that the mechanism of action of these molecules 
involves an electrophilic alkylation and cross-linking of DNA (Gandhi, 2002), where the N-2-
chloroethyl substituent plays an essential role, generating a highly reactive aziridinium 
electrophile that reacts with nucleophiles present in the biomolecules after binding. This 
chemical reactivity has also been employed in the development of GPCR covalent ligands 
(Weichert and Gmeiner, 2015).  We hypothesized that a similar mechanism could take place in 
our case and explain some of the pharmacological effects observed with OptoGluNAM4.1. A 
light-dependent NAM effect was maintained in mGlu4 expressing cells even after extensive 
washout of the allosteric ligand (Figure S2B). This could indicate the conjugation of the 
compound to the protein receptor, compatible with the precedents of the reactivity of 2-
chloroethyl anilines after binding to DNA or proteins. To better study this phenomenon, single 
cell experiments were conducted in which a meticulous washing protocol was applied (Figure 
2g and S2C). Again, we observed that the antagonistic effect persisted and that this could be 
switched off after illumination and restored in the dark, indicating the photoreversible 
receptor activation after removal of the ligand in solution. These results were in contrast with 
those obtained with the closely related compound 2 (Figure 2g and S2C) containing a hydroxyl 
group instead of the chlorine atom at the nitrogen substituent (Figure S2B). Of note, 
compound 2 is unable to chemically react with the protein residues but it conserves antagonist 
properties similar to OptoGluNAM4.1 albeit at higher concentration (Figure S2B). We 
independently confirmed this permanent effect in inositol phosphate end point assays.  When 
OptoGluNAM4.1 was incubated for 20 min and after a thorough washing protocol, a dose-
response of the mGlu4 agonist L-AP4 corroborated a remaining NAM effect, evidenced by the 
inhibition of the constitutive activity (Figure 2h). This effect was decreased by the application 
of blue light, thus suggesting that the activity was due to the presence of covalently bound 
OptoGluNAM4.1 (Figure 2i). GPCR covalent allosteric ligands are scarce (Davie et al., 2014) in 
spite of their singular pharmacological profile. 
We next implemented in vivo assays to determine OptoGluNAM4.1 activity in animal behavior. 
We first tested its mGlu4 NAM activity in a mouse model of inflammatory chronic pain (Vilar et 
al., 2013). One week after the complete Freund’s adjuvant (CFA) injection, an increase of 
mechanical hypersensitivity was observed for all animal groups, which was reduced by 
activation of spinal mGlu4 receptors following intrathecal injection of the mGlu4 orthosteric 
agonist LSP4-2022 (Vilar et al., 2013). OptoGluNAM4.1 was able to block the analgesic effect 
induced by LSP4–2022 (Figure 3a and S3) in line with its mGlu4 antagonist activity whereas 
OptoGluNAM4.1 alone did not have any measurable effect.  At the concentrations used here, 
the LSP4-2022 inhibition of mechanical hypersensitivity is lost in mGlu4 KO animals (Vilar et al., 
2013) and therefore this compound is believed  to selectively exert its effects through the 
mGlu4 receptor. The reversal of LSP4-2022 physiological effects by OptoGluNAM4.1 suggests 
that its action is likely exerted through mGlu4, although a partial contribution of mGlu7 
antagonism cannot be ruled out (Figure S1).  Overall, these results confirmed that 
OptoGluNAM4.1 is active and suitable for in vivo experimentation in mice.  
To test the light dependent activity in vivo we set up behavioral assays in transparent zebrafish 
larvae, which are amenable to illumination (Portugues et al., 2013). In comparison to 
mammals, the mGlu family of receptors in zebrafish have similar expression patterns and high 
amino acid sequence similarity (Haug et al., 2013). The activity of OptoGluNAM4.1 in water 
was evaluated by monitoring zebrafish locomotion. In the dark, OptoGluNAM4.1 treatment 
increased the free-swimming distance over untreated control animals (Figure 3b).  We next 
compared its effects with those exerted by Alloswitch-1, an azobenzene selective NAM of 
mGlu5 (Pittolo et al., 2014).  In the absence of illumination, Alloswitch-1 was found to exert an 
inhibitory action of the fish locomotion (Figure S3 and Movie S5) over that of untreated 
controls. The opposite effects found for OptoGluNAM4.1 and Alloswitch-1 on animal behavior 
(Figure 3b and Figure S3) are consistent with the opposite synaptic roles of these receptors. 
Indeed, the activation of mGlu4 (and also mGlu7) is known to inhibit synaptic glutamate release 
whereas mGlu5 has a positive modulatory effect on neuronal activity (Nicoletti et al., 2011). 
We next tested the effect of cis-trans isomerization by illumination of the zebrafish larvae. In 
vivo optical control of OptoGluNAM4.1 and Alloswitch-1 on Zebrafish demonstrated 
reversibility (Figure 3c, Figure S3c,e and Movies S3-5). The increase of the free-swimming 
distance observed in animals treated with OptoGluNAM4.1 over the untreated control group, 
was reduced to similar levels upon illumination of the larvae with blue light. On the contrary, 
the reduced free-swimming distance elicited in vivo by Alloswitch-1 was not only reversed by 
380 nm illumination but increased over untreated controls, in agreement with the activity 
rebounding previously reported in a heterologous cellular system expressing mGlu5 (Pittolo et 
al., 2014). It is worth noting the biological activity of these photoswitchable NAM compounds 
and the light-dependent effects induced in cells and living animals, thus highlighting the 
usefulness of photopharmacology in the discovery of new pharmacological paradigms.  
 
Significance 
OptoGluNAM4.1 is the first mGlu4 NAM compound with in vivo activity described to date. It 
can be useful as a tool to investigate the effects of mGlu4 receptor (and eventually mGlu7) both 
in cells and in living animals, and amenable to dissect the physiological roles of this receptor in 
the nervous system. Moreover, the OptoGluNAM4.1 advantageous photoswitch properties 
with blue light isomerization and fast relaxation in the dark facilitate the safe and efficient 
control of receptor activity with a single illumination wavelength.  OptoGluNAM4.1 permanent 
activity in endogenous mGlu4 after washing out further increases the versatility of the 
photoswitchable ligand, expanding the molecular tool set in photopharmacology.  
 
Experimental Procedures 
Synthesis of molecules. 
A description of the synthesis of compounds OptoGluNAM4.1 (1) and compound 2 is given in 
the Supplemental Information. 
 
In vitro mGlu receptor functional assay. 
HEK 293 cells were cultured and transfected by electroporation for expression of all rat mGlu 
receptors. We estimated IP accumulation using the IP-One HTRF kit (Cisbio Bioassays) both in 
dark and violet light illumination (LED plate, FCTecnics) as previously reported (Pittolo et al., 
2014). All points were realized in triplicate and read with a RUBYstar HTRF HTS microplate 
reader (BMG Labtech). Dose–response curves were fitted using Prism software (GraphPad, La 
Jolla, CA, USA). See Supplemental Methods for detailed procedure. 
Molecular modeling 
Following the protocol described previously (Rovira et al., 2015), a model of mGlu4 was 
generated with Modeller 9.12 using the crystal structure of mGlu5. OptoGluNAM4.1 was 
introduced by docking using AutoDock Vina. Discovery studio visualizer (Accelrys Software Inc., 
San Diego, CA, USA) and Jalview 2.8 were used for protein structure and sequence analysis, 
respectively. See Supplemental Methods for detailed procedure. 
Photochemical characterization. 
Absorption spectra were recorded on a Varian Cary 300 UV-Vis spectrophotometer (Agilent 
Technologies) using a quartz cuvette. Photoisomerization was accomplished by irradiation with 
a 430 nm-LED array (FCTecnics) or 630 nm-LED (Photo Activation Universal Light (PAUL), 
Geniul). Transient absorption measurements were registered in a ns laser flash-photolysis 
system (LKII, Applied Photophysics) equipped with a Nd:YAG laser (Brilliant, Quantel) and a 
photomultiplier tube (Hamamatsu). See Supplemental Methods for detailed procedure. 
Single-cell calcium imaging and photostimulation. 
HEK tsA201 cells were cultured, transfected and seeded as previously reported (Pittolo et al., 
2014). Fura-2 AM was loaded into the cells, excited with a Polychrome V light source (Till 
Photonics) and the resulting images acquired with an inverted digital microscope (iMic, Till 
Photonics). The fluorescence ratio was calculated by the software (LA Arivis Browser 1.6, 
Arivis). Variations in intracellular calcium were evaluated with IgorPro 6.0.5 (WaveMetrics). 
Dose-response curves were fitted with Prism (GraphPad, La Jolla, CA, USA). Videos were edited 
from raw images using Fiji (ImageJ). See Supplemental Methods for detailed procedure. 
 
Mechanical allodynia in a mouse pain model. 
Von Frey assay in 8- to 10-weeks-old C57BL/6 mice was used to evaluate the effect of mGlu4 
compounds. We chose a chronic inflammatory pain model induced by unilateral intraplantar 
injection of complete Freund’s adjuvant (CFA; Mycobacterium tuberculosis; Sigma). 
Compounds were intrathecally administered. Data were analyzed with Prism software 
(GraphPad, La Jolla, CA, USA). See Supplemental Methods for detailed procedure. 
Zebrafish 
Wild-type TL (Tupfel long fin) specimen were used for these experiments. Monitoring of the 
animal locomotion was made with the Zebrabox using the optogenetic module (Viewpoint Life 
Sciences). One larvae per well was placed in a 96 well plate (BD Falcon) with E3 medium. Data 
were analyzed using with Prism software (GraphPad, La Jolla, CA, USA). See Supplemental 
Methods for detailed procedure. 
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Figure Legends 
Figure 1| OptoGluNAM4.1 is a negative allosteric modulator of mGlu4.  
(a) Chemical structure of OptoGluNAM4.1 compound containing the azobenzene moiety. (b) 
Dose-response curves of the orthosteric agonist L-AP4 or the allosteric agonist VU015041 in 
the presence of different doses of OptoGluNAM4.1 in wild type, a mutated mGlu4 receptor( 
which is insensitive to glutamate), and an ECD-truncated mGlu4 receptor. (c) Localization of the 
OptoGluNAM4.1 binding site within a model of the transmembrane domain proposed by a 
protein docking study. Two amino acid positions (L756S and V826M) topologically delimit the 
allosteric binding pocket. (d) Dose-response curves for a wild type and mutated receptors after 
stimulation with the agonist both in presence and in absence of OptoGluNAM4.1. Each data 
point corresponds to mean ± SEM of at least 3 experiments performed.  
Figure 2 | OptoGluNAM4.1 can be dynamically regulated by blue light.  
(a) OptoGluNAM4.1 photoisomerization from trans to cis configuration after illumination with 
blue light. (b) Absorbance spectrum of OptoGluNAM4.1 (50 μM in DMSO) in dark (black line) 
and after illumination with 430 nm light (blue line) for 3 min or 630 nm light (red line) for 1 
min. (c) Thermal isomerization of OptoGluNAM4.1 from cis to trans in dark (50 µM, PBS:DMSO 
98:2) after a single ns laser pulse (t = 0) at λexc = 355 nm and 25°C. Solid thick red line 
corresponds to monoexponential fitting of the experimental data. (d) Time course of 
intracellular calcium in an mGlu4-expressing HEK cell, challenged with the mGlu4 agonist L-AP4 
(0.3 µM, red bar) in absence or in presence of OptoGluNAM4.1 (10 µM, blue bar). Blue boxes 
indicate illumination at 430 nm. (e-f) Quantification of agonist (1 µM L-AP4) and light (λ = 430 
nm) dependent mGlu4 activation in presence of OptoGluNAM4.1 (e, 10 µM, n=12) or LY341495 
(f, 100 µM, n=3) from results indicated in (d). Differences in receptor activation are significant 
compared to L-AP4 alone (maximum response) during application of OptoGluNAM4.1 under 
blue light (p < 0.05) and after the addition of L-AP4 (p < 0.001) but not when both L-AP4 and 
blue light are applied. No response was observed during LY341495 application in any 
condition. (g) Dose-response of L-AP4 during exposure to 430 nm-light in individual mGlu4 
expressing-cells, 30 minutes after treatment (and a subsequent thorough washing) with 30 µM 
of either OptoGluNAM4.1 or the –OH substituted compound 2. Mean ± SEM from at least two 
independent experiments indicated in Figure S2C. Data normalized to the maximum response 
obtained in each cell (n ≥ 5). (h-i) Dose-response curves of L-AP4 after pre-treatment of cells 
with different concentrations of OptoGluNAM4.1 and subsequent washing both in dark and 
under blue light exposure, respectively. Each data point corresponds to mean ± SEM of at least 
3 experiments. 
Figure 3|OptoGluNAM4.1 is active in mouse and zebrafish animal models. 
(a) Pharmacological modulation of spinal mGlu4 receptors in chronic inflamed C57BL/6 mice by 
OptoGluNAM4.1 evaluated by the Von Frey method. The number of paw lifts from five 
stimulations using a noxious Von Frey filament is counted before and after inflammation 
(induced by CFA) and intrathecal treatment (IT). Animals were treated with vehicle (1% 
DMSO), LSP4-2022 (10µg/mice), OptoGluNAM4.1 (100µM) and LSP4-2022/ OptoGluNAM4.1  
(10µg/mice and 100µM, respectively). All the results are expressed as mean ± SEM. (b) 
Quantification of the total accumulated free-swimming distance of the zebrafish larvae for 
every 5 minutes in presence or in the absence of OptoGluNAM4.1. (c) Quantification of the 
accumulated free-swimming distance of the zebrafish larvae for cycles of 1 min in dark or 
under blue light (430 nm) upon OptoGluNAM4.1 (10µM) treatment. (d) Zebrabox setup with 
the optogenetic module allowing for the very precise control of light conditions during 
behavioral experiments. Individual zebrafish larvae can be independently tracked in each well 
(scale bar 200 μm). For all zebrafish experiments, each data point corresponds to mean ± SEM 
of 12 animals from 2 independent experiments. Statistical differences from control are 
denoted for adjusted p-values as follows: *P < 0.05;  **P < 0.01; ***P < 0.001;  ****P <0.0001.  
